FDA Announces Final Guidance for Abbreviated New Drug Applications Submission Practices

Summary

The Food and Drug Administration (FDA) has released a final guidance to help pharmaceutical companies prepare and submit abbreviated new drug applications (ANDAs) to the FDA, aiming to reduce delays in approval by identifying and addressing common deficiencies.